Funding Details
- Awarder
- Inbox
- Date Award
- May 16, 2025
- Vertical
- Life Sciences
- Funding URL
- View Funding Page
Company Info
- Traction
- Results of a prospective, multicenter NIH-sponsored study of the Syn-One Test were published in JAMA in 2024 demonstrating >95% sensitivity overall in patients with a clinically determined synucleinopathy.
- Company Description
- CND Life Sciences supports the care of patients facing the potential diagnosis of neurodegenerative disease and other neurological conditions. The company developed the Syn-One Test to help clinicians diagnose synucleinopathies that include Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
- Market
- Neurodegenerative diseases
- Location
-
Scottsdale,
Arizona,
USA
- Coinvestors
- Cambrian Capital Partners, Tanis Ventures, Lupo Labs, Top Corner Capital, HonorHealth, Triana, Gold Bench Capital, BlueStone Ventures, Labcorp, MBX Capital, Vilas Ventures
Links